Menu Back toSession 1: Setting up the Scene: More than 10 Years of ATMPs in Europe

Innovative Therapies in Europe

DIA-EUCOPE Workshop: 5 Years of ATMPs on the Market - Lessons Learned

Session 1: Setting up the Scene: More than 10 Years of ATMPs in Europe

Session Chair(s)

Jacquelyn  Awigena-Cook, MSc

Jacquelyn Awigena-Cook, MSc

  • Director, Global Regulatory Policy & Intelligence
  • Bristol Myers Squibb, United Kingdom

Topics covered in this session include:

  • The inclusion of Innovation Therapies in the Pharma Strategy
  • The last 10 years of Innovative Therapies in the EU
  • Complexities in cell and gene therapies development: how have we accommodated them in our reimbursement systems.


Emil Andrei  Cochino, MD, MHS

Reflections from the Various Stakeholders

Emil Andrei Cochino, MD, MHS

  • Scientific Officer, Risk Management Specialist, Office of vaccines and therapies
  • European Medicines Agency, Netherlands
Anne  Kerber

Anne Kerber

  • SVP Head of Cell Therapy Development
  • Bristol Myers Squibb , Germany
Antonella  Cardone

Antonella Cardone

  • Director
  • Cancer Patients Europe, Belgium
François  Houyez

François Houyez

  • Treatment Information and Access Director, Health Policy Advisor
  • European Organisation for Rare Diseases (EURORDIS), France

Contact us

Registration Questions?

Send Email
+41 61 225 51 51